Metabolic Dysfunction-Associated Steatotic Liver Disease and the Cardiovascular System

Trends in Cardiovascular Medicine, Journal Year: 2025, Volume and Issue: 35(4), P. 258 - 265

Published: Jan. 21, 2025

Language: Английский

---

Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma

Medicina, Journal Year: 2025, Volume and Issue: 61(1), P. 88 - 88

Published: Jan. 7, 2025

Introduction: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) stems from disrupted lipid metabolism in the liver, often linked to obesity, type 2 diabetes, and dyslipidemia. In Mexico, where obesity affects 36.9% of adults, MASLD prevalence has risen, especially with metabolic syndrome affecting 56.31% by 2018. can progress Steatohepatitis (MASH), 5.27% globally, leading severe complications like cirrhosis hepatocellular carcinoma. Background: Visceral fat distribution varies gender, impacting development due hormonal influences. Insulin resistance plays a central role pathogenesis, exacerbated high-fat diets specific fatty acids, hepatic steatosis. Lipotoxicity saturated acids further damages hepatocytes, triggering inflammation fibrosis progression MASH. Diagnosing traditionally involves invasive liver biopsy, but non-invasive methods ultrasound transient elastography are preferred their safety availability. These detect steatosis reasonable accuracy, offering alternatives biopsy despite varying sensitivity specificity. Conclusions: as disorder underscores its impact on public health, necessitating improved awareness early management strategies mitigate diseases.

Language: Английский

---

Dietary flaxseed: Cardiometabolic benefits and its role in promoting healthy aging

GeroScience, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 16, 2025

Flaxseed, a rich source of omega-3 polyunsaturated fatty acid alpha-linolenic (ALA), lignans, and soluble fiber, has attracted attention for its potential to improve multiple cardiometabolic risk factors. While benefits are well-recognized, comprehensive evaluations direct impact on clinical outcomes, such as the prevention or progression diseases, remain limited. Additionally, support healthy aging longevity through fundamental biological mechanisms not been fully elucidated. This review synthesizes existing research flaxseed supplementation, highlighting effects factors underlying mechanisms, broader implications health promotion aging. Findings demonstrate that supplementation significantly improves several factors, including body weight, mass index, lipid levels, blood pressure, glycemic measures, markers inflammation (e.g., C-reactive protein interleukin-6), oxidative stress, liver enzymes. Blood pressure reductions range from approximately 2 15 mmHg systolic 1 7 diastolic with magnitude influenced by dose, duration, baseline profiles. evidence linking hypertension, metabolic syndrome, dysfunction-associated steatotic disease, type diabetes, chronic kidney cardiovascular disease is limited, bioactive components-ALA, fiber-are strongly associated reduced risks these conditions. The mediated pathways, anti-inflammatory antioxidant effects, improved glucose metabolism insulin sensitivity, modulation gut microbiota, enhanced vascular health. Beyond may influence key processes relevant aging, underscoring promote longevity. Optimal appear be achieved ground whole at doses ≥ 30 g/day least 12 weeks, particularly among individuals high risk. Future should focus elucidating flaxseed's action, clarifying role in prevention, refining dietary recommendations harness interventions.

Language: Английский

---

Development and validation of machine learning models for MASLD: based on multiple potential screening indicators

Frontiers in Endocrinology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 21, 2025

Background Multifaceted factors play a crucial role in the prevention and treatment of metabolic dysfunction-associated steatotic liver disease (MASLD). This study aimed to utilize multifaceted indicators construct MASLD risk prediction machine learning models explore core within these models. Methods were constructed based on seven algorithms using all variables, insulin-related demographic characteristics other indicators, respectively. Subsequently, partial dependence plot(PDP) method SHapley Additive exPlanations (SHAP) utilized explain roles important variables model filter out optimal for constructing model. Results Ranking feature importance Random Forest (RF) eXtreme Gradient Boosting (XGBoost) found that both homeostasis assessment insulin resistance (HOMA-IR) triglyceride glucose-waist circumference (TyG-WC) first second most variables. The with top 10 was superior previous PDP SHAP methods further screen best (including HOMA-IR, TyG-WC, age, aspartate aminotransferase (AST), ethnicity) model, mean area under curve value 0.960. Conclusions HOMA-IR TyG-WC are predicting risk. Ultimately, our AST, ethnicity.

Language: Английский

---

The correlation between heavy metal ions in blood and metabolic dysfunction-associated steatotic liver disease from 1999 to 2018 based on NHANES data

Frontiers in Public Health, Journal Year: 2025, Volume and Issue: 12

Published: Jan. 7, 2025

Metabolic-associated steatohepatitis and liver fibrosis (MASLD) is a growing public health concern, with environmental factors potentially playing role in its development. This study aimed to investigate the associations between serum cadmium mercury levels risk of MASLD nationally representative sample from United States. Data National Health Nutrition Examination Survey 1999 2018 were analyzed. Serum concentrations measured, was defined based on established criteria. Logistic regression models used assess metal MASLD, adjustments for potential confounders. Stratified analyses restricted cubic spline curves employed examine subgroup differences nonlinear relationships. The revealed significant inverse likelihood MASLD. Individuals highest quartiles had lower odds compared those lowest (Model 3: Cadmium Q4 vs. Q1, Mercury Q1). showed stronger older adults, males, never smokers cadmium, females individuals without diabetes mercury. Nonlinear dose-response indicated critical thresholds beyond which dynamics changed. Higher associated notable variations across subgroups. These findings challenge conventional understanding these heavy metals as universally harmful highlight need further research unravel complex interplay exposures pathophysiology.

Language: Английский

---

Metabolic and alcohol-associated liver disease (MetALD): a representation of duality

npj gut and liver., Journal Year: 2025, Volume and Issue: 2(1)

Published: Jan. 10, 2025

MetALD is a recently coined term that refers to systemic entity describe patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and simultaneous moderate alcohol consumption. The deleterious association of risk factors synergistically increases the development steatohepatitis, fibrosis, hepatocellular carcinoma (HCC). Despite its increasing incidence, pathophysiological mechanisms triggering damage in remain unclear. This review aims summarize prevalence, pathophysiology MetALD, taking into account latest clinical translational aspects.

Language: Английский

---

Association of prebiotic/probiotic intake with MASLD: evidence from NHANES and randomized controlled trials in the context of prediction, prevention, and a personalized medicine framework

The EPMA Journal, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 29, 2025

Language: Английский

---

Insights into the results of Resmetirom trials: Can a thyroid hormone receptor agonist be the holy grail of MASH therapy?

Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown, P. 108811 - 108811

Published: Feb. 1, 2025

Despite the heavy individual patient and socioeconomic burden of metabolic dysfunction-associated steatohepatitis (MASH), until recently, no pharmacological therapy for MASH was approved, with available treatment options geared towards associated cardiometabolic risk factors. Accelerated approval resmetirom, a thyroid hormone receptor-β agonist to be used in conjunction diet exercise, marks significant step forward MASH, offering tempered optimism healthcare providers millions patients around world more effective management. Evidence from phase 2 3 clinical trials suggests that resmetirom has potential alleviate hepatic fibrosis inflammation significantly reduce liver lipid content. Notwithstanding this landmark event, implementation comes important challenges, example, ensuring access demonstrating effects on hard MASH-related outcomes, such as progression cirrhosis hepatocellular carcinoma. Additional considerations include evaluation co-administration other hepatoprotective treatments assessment efficacy specific sub-phenotypes. Furthermore, accumulation real-world data experience is expected help answer remaining questions about (long-term) effectiveness safety profile drug. The purpose article provide an updated critical review mechanisms action, efficacy, based latest trials, define its place within broader landscape management, highlight current knowledge gaps opportunities future research field.

Language: Английский

---

Multivitamin supplementation and its impact in metabolic dysfunction-associated steatotic liver disease

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: March 13, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging global health concern with limited therapeutic options. Multivitamins, widely consumed dietary supplements, have been proposed to modulate oxidative stress and inflammation, potentially impacting MASLD progression. However, their efficacy in reducing mortality other complications remains unclear. Using data from the UK Biobank 7 years of median follow-up period, this study assessed association between multivitamin use outcomes, including all-cause mortality, liver-related cardio-cerebrovascular (CVD), chronic kidney (CKD), individuals those without disease. Inverse probability treatment weighting (IPTW) was employed adjust for confounders. Multivitamin users showed a significantly lower risk cohort both before (HR: 0.88, 95% CI 0.81–0.95, P = 0.034) after 0.94, 0.88–1.00, 0.037) IPTW adjustment. also associated CVD 0.72, 0.68–0.76, < 0.001) CKD 0.73, 0.67–0.81, cohort. No significant reduction found or cirrhosis incidence. These findings suggest that multivitamins might provide broader protective effects populations metabolic dysfunction. Further research needed clarify role liver-specific outcomes.

Language: Английский

---

The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis

Annals of Medicine, Journal Year: 2024, Volume and Issue: 56(1)

Published: Jan. 22, 2024

Objective While studies have documented how metabolic dysfunction-associated steatotic liver disease (MASLD) can contribute to cardiovascular (CVD), whether MASLD is associated with myocardial infarction (MI) remains debateable. Herein, we systematically reviewed published articles and performed a meta-analysis determine the relationship between MI risk.

Language: Английский

---